Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of a malignant disorder (hematologic malignancies or solid tumors)
• •* Advanced disease
• •Has undergone prior allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-mismatched/haploidentical familial donor
• •Progressive or recurrent disease, as defined by any of the following (phase II):
• •* Peripheral blood blast \> 20% with bone marrow aspirate showing \> 5% leukemic cells (in patients with acute leukemia)
• •* Detection of metaphases in the marrow with the same clonal cytogenetic abnormalities as identified before HSCT (or by FISH markers, if appropriate) (in patients with acute leukemia or high-risk myelodysplastic syndromes \[MDS\])
• •* Persistent cytopenia with bone marrow aspirate showing various degrees of dysplasia involving ≥ 1 cell lineage (in patients with high-risk MDS)
• •* Enlargement of pre-existing measurable lesions by 20% according to RECIST criteria (in patients with solid tumors or lymphoma)
• •* Appearance of new metastatic lesions, including pleural effusion or ascites, radiologically typical for metastases or confirmed as such by cytology (in patients with solid tumors or lymphoma)
• •Measurable disease (phase II)
• •PATIENT CHARACTERISTICS:
• •Karnofsky performance status 70-100%
• •Total bilirubin \< 3.0 mg/dL
• •AST \< 5 times upper limit of normal
• •Creatinine \< 3 mg/dL
• •Not pregnant or nursing
• •No clinically evident cardiac or pulmonary failure
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics